This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Neurology  • Cerebrovascular Disease  • Stroke  • Alert me on articles by topic

Daniel F. Hanley, MD

JAMA. 2004;291:621-622.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Stroke prevention represents a critical health challenge. The demographics of aging and the association of stroke with aging bring together factors that compel a concerted effort to limit the individual and societal risks of a worldwide epidemic of stroke.¹ As a disease, stroke functions on 2 biological frontiers: aging and brain vascular function. Society has recognized the epidemic of atherosclerotic vascular disease for the last 4 decades and has begun to deal with the cardiac consequences of atherosclerosis. These efforts are apparent in the public domain and in the physician's office. Multiple acute interventions and prevention programs are available to limit acute disease and delay or reverse coronary artery narrowing and help prevent progression to subsequent myocardial infarctions.

Unfortunately, such is not the case with stroke. Embolic stroke and carotid stenosis represent treatable subsets of stroke etiologies. Aspirin can provide partial prevention, but the majority of . . . [Full Text of this Article]

Author Affiliation: Division of Brain Injury Outcomes, Johns Hopkins Medical Institutions, Baltimore, Md.

RELATED ARTICLES

Lowering Homocysteine in Patients With Ischemic Stroke to Prevent Recurrent Stroke, Myocardial Infarction, and Death: The Vitamin Intervention for Stroke Prevention (VISP) Randomized Controlled Trial
James F. Toole, M. René Malinow, Lloyd E. Chambless, J. David Spence, L. Creed Pettigrew, Virginia J. Howard, Elizabeth G. Sides, Chin-Hua Wang, and Meir Stampfer
JAMA. 2004;291(5):565-575.
ABSTRACT | FULL TEXT  

Antiphospholipid Antibodies and Subsequent Thrombo-occlusive Events in Patients With Ischemic Stroke
APASS Investigators
JAMA. 2004;291(5):576-584.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

From the Library
Br. J. Ophthalmol. 2004;88:726-726.
FULL TEXT  

Reducing homocysteine levels does not prevent stroke recurrence
Gottlieb
BMJ 2004;328:307.
FULL TEXT